SARS-CoV and SARS-CoV-2 S protein pseudotyped lentiviruses
We help our customers to assemble SARS-CoV and SARS-CoV-2 S protein pseudotyped lentiviruses. These particles carry reporters that can be used for antiviral drug screening or the quantification of neutralizing antibodies. Customers can provide us with the reporter construct of your choice, and we will assemble particles within a week. Please contact us by email: firstname.lastname@example.org
We also have several pre-assembled, concentrated (60 x concentrated) particles that are available for your initial testing. These particles are provided with a free sample of our proprietary SARS-CoV-2 Pseudovirus Infection Enhancer (CoV-2-PIE, Cat# CoV2-01) that can greatly promote productive viral infection. CoV-2-PIE can be used to facilitate the infection of a variety of host cells. CoV-2-PIE can enhance viral infection rates by 3 to 20 fold.
- SARS-CoV and SARS-CoV-2 pseudovirus transduction of target cells for viral entry and functional studies
- Anti-SARS-CoV and SARS-CoV-2 drug screening
- Anti-SARS-CoV and SARS-CoV-2 neutralizing antibody screening
Table 1. 60 X concentrated, SARS-CoV and SAR-CoV-2 pseudoviral particles
Example of results:
SARS-CoV-2 S protein pseudotyped lentiviral particle transduction of Vero E6 cells (Left):
Vero E6 cells were transduced with SARS-CoV-2-S(Luc) lenti-pseudovirus (with a luciferase reporter) in the presence of CoV-2-PIE. Reporter expression was quantified at 3 days post transduction (luciferase assay).
SARS-CoV S protein pseudotyped lentiviral particle transduction of Vero cells (Right):
Vero cells were transduced with SARS-CoV-S(GFP) lenti-pseudovirus (with a GFP reporter) in the presence of CoV-2-PIE. Reporter expression was quantified at 2 days post transduction (GFP flow cytometry).
SARS-CoV and CoV-2 pseudoviruses are intended for Research Use Only and are not for diagnostic or therapeutic purposes or uses in humans or animals.